3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
Gemcitabine
20
Fluorouracil
14
Cisplatin
10
Capecitabine
10
Leucovorin
8
durvalumab
6
Oxaliplatin
6
Erlotinib Hydrochloride
4
Sorafenib
3
Radiotherapy
3
trifluridine tipiracil drug combination
2
trametinib
2
regorafenib
2
pembrolizumab
2
olaparib
2
ceralasertib
2
Specimen Handling
2
Radiosurgery
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Irinotecan
2
Filgrastim
2
AZD 6244
2
zimberelimab
1
tremelimumab
1
titanium silicide
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
seribantumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bile Duct Neoplasms
×
Standard of Care
×
Clear all
NCT04099888
2023-09-11
RELEASE
PCI Biotech AS
Phase 2
Terminated
41 enrolled
17 charts